Patents by Inventor Hiroshi KUNUGI

Hiroshi KUNUGI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11655493
    Abstract: A marker for determining a mental disease is provided. The marker can be used in an objective diagnosis of such a mental disease. The marker contains one or more enterobacteria of Bifidobacterium, Lactobacillus, Lactobacillus brevis, Lactobacillus reuteri subgroup, Lactobacillus sakei subgroup, Atopobium cluster, Bacteroides fragilis group, Enterococcus, Clostridium coccoides group, Clostridium leptum subgroup, Staphylococcus, Clostridium perfringens, and Enterobacteriaceae.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: May 23, 2023
    Assignees: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Hiroshi Kunugi, Emiko Aizawa, Hirokazu Tsuji
  • Patent number: 11555221
    Abstract: The object of the invention is to provide a method for easily and objectively detecting mood disorders in a subject by measuring the expression levels of prescribed genes in the peripheral blood of the subject, the reliability of the detection result being high. The invention also provides a method for detecting mood disorders in a subject, the method having a step for measuring the gene expression levels of ribosomal protein genes, CDKN1C, or any combination thereof in the peripheral blood derived from the subject, and detecting whether or not the subject has mood disorders on the basis of the measurement results.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: January 17, 2023
    Inventors: Seiji Nakamura, Yohei Ishizawa, Ryo Matoba, Kenichi Matsubara, Hiroshi Kunugi, Hiroaki Hori
  • Patent number: 11174317
    Abstract: The present invention provides a novel therapeutic agent for mental illness. The therapeutic agent for mental illness comprises an IL-6 inhibitor as an active ingredient.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: November 16, 2021
    Assignees: National Center of Neurology and Psychiatry, Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroshi Kunugi, Chisato Wakabayashi
  • Publication number: 20200191768
    Abstract: A non-transitory computer-readable medium stores a program that, when executed, causes a computer to (i) cause a biomarker-measuring apparatus to measure concentrations of biomarkers, including a concentration of 3-hydroxybutyrate, in a blood sample collected from a subject to be tested, (ii) acquire the concentrations of the biomarkers measured by the biomarker-measuring apparatus, (iii) calculate a discriminant value based on the concentrations of the biomarkers, (iv) evaluate severity of depression of the subject or predict a symptom of depression of the subject based on the discriminant value, and (v) output results obtained from evaluating the severity of depression of the subject or from predicting the symptom of depression of the subject.
    Type: Application
    Filed: October 31, 2019
    Publication date: June 18, 2020
    Applicants: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Takahiro KATO, Daiki SETOYAMA, Dongchon KANG, Shigenobu KANBA, Ryota HASHIMOTO, Hiroshi KUNUGI, Kotaro HATTORI
  • Publication number: 20200108040
    Abstract: An agent for improving brain function and agent for preventing or treating cognitive impairment, which comprises: 5 to 50 parts by weight of a protein; 5 to 80 parts by weight of a medium-chain fatty acid triglyceride as a lipid; and 1 to 50 parts by weight of a carbohydrate, per 100 parts by weight.
    Type: Application
    Filed: December 5, 2019
    Publication date: April 9, 2020
    Applicants: THE FOOD SCIENCE INSTITUTE FOUNDATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Hiroshi KUNUGI, Miho OTA, Junko MATSUO, Yoshitatsu ICHIHARA
  • Publication number: 20200024663
    Abstract: The object of the invention is to provide a method for easily and objectively detecting mood disorders in a subject by measuring the expression levels of prescribed genes in the peripheral blood of the subject, the reliability of the detection result being high. The invention also provides a method for detecting mood disorders in a subject, the method having a step for measuring the gene expression levels of ribosomal protein genes, CDKN1C, or any combination thereof in the peripheral blood derived from the subject, and detecting whether or not the subject has mood disorders on the basis of the measurement results.
    Type: Application
    Filed: September 25, 2017
    Publication date: January 23, 2020
    Inventors: Seiji NAKAMURA, Yohei ISHIZAWA, Ryo MATOBA, Kenichi MATSUBARA, Hiroshi KUNUGI, Hiroaki HORI
  • Publication number: 20180348195
    Abstract: An objective biomarker is capable of evaluating the severity of depression and is clinically useful. The biomarker is used for evaluating the severity of depression, and includes at least one compound selected from the group made of 4-aminobutyric acid (? (gamma)-aminobutyric acid: GABA), arginine, argininosuccinate, isoleucine, indole carboxaldehyde, potassium indoleacetate, carnitine, acetylcarnitine, ornithine, xanthurenate, kynurenate, kynurenine, citrate, creatine, creatinine, glutamine, dimethylglycine, serotonin, taurine, trimethyloxamine (TMAO), tryptophan, norvaline, 3-hydroxybutyrate, phenylalanine, proline, betaine, and lysine.
    Type: Application
    Filed: October 31, 2016
    Publication date: December 6, 2018
    Applicants: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Takahiro KATO, Daiki SETOYAMA, Dongchon KANG, Shigenobu KANBA, Ryota HASHIMOTO, Hiroshi KUNUGI, Kotaro HATTORI
  • Publication number: 20180186887
    Abstract: The present invention provides a novel therapeutic agent for mental illness. The therapeutic agent for mental illness comprises an IL-6 inhibitor as an active ingredient.
    Type: Application
    Filed: June 3, 2016
    Publication date: July 5, 2018
    Applicants: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Hiroshi KUNUGI, Chisato WAKABAYASHI
  • Publication number: 20180169052
    Abstract: An agent for improving brain function and agent for preventing or treating cognitive impairment, which comprises: 5 to 50 parts by weight of a protein; 5 to 80 parts by weight of a medium-chain fatty acid triglyceride as a lipid; and 1 to 50 parts by weight of a carbohydrate, per 100 parts by weight.
    Type: Application
    Filed: July 23, 2015
    Publication date: June 21, 2018
    Applicants: THE FOOD SCIENCE INSTITUTE FOUNDATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Hiroshi KUNUGI, Miho OTA, Junko MATSUO, Yoshitatsu ICHIHARA
  • Publication number: 20180100177
    Abstract: A marker for determining a mental disease is provided. The marker can be used in an objective diagnosis of such a mental disease. The marker contains one or more enterobacteria of Bifidobacterium, Lactobacillus, Lactobacillus brevis, Lactobacillus reuteri subgroup, Lactobacillus sakei subgroup, Atopobium cluster, Bacteroides fragilis group, Enterococcus, Clostridium coccoides group, Clostridium leptum subgroup, Staphylococcus, Clostridium perfringens, and Enterobacteriaceae.
    Type: Application
    Filed: April 15, 2016
    Publication date: April 12, 2018
    Applicants: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Hiroshi KUNUGI, Emiko AIZAWA, Hirokazu TSUJI